XML 60 R48.htm IDEA: XBRL DOCUMENT v3.8.0.1
License agreements - Agenus (Details)
$ / shares in Units, $ in Thousands, shares in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 14, 2017
USD ($)
$ / shares
Feb. 01, 2017
USD ($)
$ / shares
shares
Feb. 28, 2017
USD ($)
Nov. 30, 2015
item
Feb. 28, 2015
Jan. 31, 2015
item
Mar. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Mar. 31, 2017
USD ($)
Dec. 31, 2017
USD ($)
License agreements                    
Long term investment             $ 165,972 $ 134,356 [1]   $ 134,356 [1]
Research and development expense             303,103   $ 407,920  
Unrealized gain (loss) on long term investments             $ 22,679   (5,814)  
Agenus                    
License agreements                    
Number of program targets | item       3   4        
Royalty payments on future global net sales (as a percent)             15.00%      
Period of notice for termination of license agreement     12 months              
Agenus | Development, Regulatory and Commercialization Milestones | Minimum                    
License agreements                    
Royalty payments on future global net sales (as a percent)             6.00%      
Agenus | Development, Regulatory and Commercialization Milestones | Maximum                    
License agreements                    
Royalty payments on future global net sales (as a percent)             12.00%      
Additional milestone payments under the license agreement     $ 510,000              
Agenus | Development Milestones                    
License agreements                    
Upfront payment under license agreement                   20,000
Agenus                    
License agreements                    
Long term investment             $ 83,700 57,900   57,900
Research and development expense             $ 1,900   7,700  
Shares owned following stock purchase (as a percent)     11.00%   9.00%          
Ownership percentage (as a percent)             17.00%      
Unrealized gain (loss) on long term investments             $ 25,800   (7,700)  
Total revenues               8,400    
Net income (loss)               35,000    
Agenus | Accrued and other liabilities                    
License agreements                    
Accrued and other liabilities             $ 2,800 $ 3,200   $ 3,200
Agenus | Stock purchase agreement                    
License agreements                    
Total consideration paid $ 60,000                  
Long term investment                 39,500  
Research and development expense                 $ 20,500  
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares   10.0                
Purchase price of common stock   $ 60,000                
Per share price | $ / shares $ 4.40 $ 6.00                
Discount for lack of marketability $ 4,500                  
Fair value of shares on the issuance date $ 39,500                  
[1] The condensed consolidated balance sheet at December 31, 2017 has been derived from the audited financial statements at that date.